Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective multicentre randomised all-comers trial to assess the safety and effectiveness of the thin-strut sirolimus-eluting coronary stent SUPRAFLEX: rationale and design of the Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) trial.
Modolo R, Chichareon P, Kogame N, Asano T, Chang CC, de Winter RJ, Kaul U, Zaman A, Spitzer E, Takahashi K, Katagiri Y, Soliman OII, van Es GA, Morel MA, Onuma Y, Serruys PW. Modolo R, et al. Among authors: kaul u. EuroIntervention. 2019 Jul 20;15(4):e362-e369. doi: 10.4244/EIJ-D-18-00499. EuroIntervention. 2019. PMID: 30066672 Free article. Clinical Trial.
The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
Grube E, Chevalier B, Smits P, Džavík V, Patel TM, Mullasari AS, Wöhrle J, Stuteville M, Dorange C, Kaul U; SPIRIT V Investigators. Grube E, et al. Among authors: kaul u. JACC Cardiovasc Interv. 2011 Feb;4(2):168-75. doi: 10.1016/j.jcin.2010.11.006. JACC Cardiovasc Interv. 2011. PMID: 21349455 Free article.
The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberté paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions.
Grube E, Chevalier B, Guagliumi G, Smits PC, Stuteville M, Dorange C, Papeleu P, Kaul U, Džavík V. Grube E, et al. Among authors: kaul u. Am Heart J. 2012 May;163(5):867-875.e1. doi: 10.1016/j.ahj.2012.02.006. Epub 2012 Apr 11. Am Heart J. 2012. PMID: 22607866 Clinical Trial.
Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes.
Kaul U, Bangalore S, Seth A, Arambam P, Abhaichand RK, Patel TM, Banker D, Abhyankar A, Mullasari AS, Shah S, Jain R, Kumar PR, Bahuleyan CG; TUXEDO–India Investigators. Kaul U, et al. N Engl J Med. 2015 Oct 29;373(18):1709-19. doi: 10.1056/NEJMoa1510188. Epub 2015 Oct 14. N Engl J Med. 2015. PMID: 26466202 Free article. Clinical Trial.
First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial.
Seth A, Onuma Y, Costa R, Chandra P, Bahl VK, Manjunath CN, Mahajan AU, Kumar V, Goel PK, Wander GS, Kalarickal MS, Kaul U, Kumar VKA, Rath PC, Trehan V, Sengottuvelu G, Mishra S, Abizaid A, Serruys PW. Seth A, et al. Among authors: kaul u. EuroIntervention. 2017 Jul 20;13(4):415-423. doi: 10.4244/EIJ-D-17-00306. EuroIntervention. 2017. PMID: 28504218 Free article. Clinical Trial.
Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial.
Zaman A, de Winter RJ, Kogame N, Chang CC, Modolo R, Spitzer E, Tonino P, Hofma S, Zurakowski A, Smits PC, Prokopczuk J, Moreno R, Choudhury A, Petrov I, Cequier A, Kukreja N, Hoye A, Iniguez A, Ungi I, Serra A, Gil RJ, Walsh S, Tonev G, Mathur A, Merkely B, Colombo A, Ijsselmuiden S, Soliman O, Kaul U, Onuma Y, Serruys PW; TALENT trial investigators. Zaman A, et al. Among authors: kaul u. Lancet. 2019 Mar 9;393(10175):987-997. doi: 10.1016/S0140-6736(18)32467-X. Epub 2019 Feb 28. Lancet. 2019. PMID: 30827782 Clinical Trial.
469 results